Effect of high dose versus low dose Atorvastatin therapy on inflammatory & coagulatory factors in type 2 diabetic patients

Phase 3

• Conditions: type 2 diabetic.; Diabetes mellitus; E10,E11,E1

• Registration Number: IRCT201502226710N5
• Lead Sponsor: Vice chancellor for research, Tabriz University of Medical Sciences Daneshgah Square Tabriz

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Patients with type2 diabetes mellitus LDL>70 ; age>18y ;TG<500; patients who don't use or stopped statin use (> 1 mth)

Exclusion criteria: type 1 diabetes Mellitus; chronic liver disease(liver enzymes more than 3 time the upper limit of normal , B or C Hepatitis ); renal failure Cr>2;pregnancy;lactation ; Chronic inflammatory diseases such as rheumatic diseases (rheumatoid arthritis and systemic lupus erythematosus); Patients with a history of anti-inflammatory drugs; In case of muscle pain and increased risk of rhabdomyolysis in patients with CPK elevation; unwillingness to participate in the study.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ow density Lipoprotein. Timepoint: At baseline and after 3 months of treatment. Method of measurement: Test.;Cholestrol. Timepoint: At baseline and after 3 months of treatment. Method of measurement: test.

Secondary Outcome Measures

Name	Time	Method
Inflammatory markers. Timepoint: At baseline and after 3 months of treatment. Method of measurement: test.;Coagulatory factor. Timepoint: At baseline and after 3 months of treatment. Method of measurement: test.